DELVE INTO AFRICAN WEALTH
DON'T MISS A BEAT
Subscribe now
Skip to content

Saltzman family, one of South Africa’s richest, loses $43.95 million from Dis-Chem stake

This follows a previous loss between Feb. 7 and Mar. 10, when their stake dropped by $45.37 million, from $473.47 million to $428.09 million.

Saltzman family, one of South Africa’s richest, loses $43.95 million from Dis-Chem stake
Ivan Saltzman

Table of Contents


Key Points

  • The Saltzman family's stake in Dis-Chem Pharmacies has dropped by nearly $44 million in under three weeks due to a decline in share price.
  • Dis-Chem's market value has fallen below $1.3 billion after a 10.59% drop in shares, impacting major shareholders like the Saltzman family.
  • The Saltzman family’s 29.3% stake has slipped from $414.84 million to $370.89 million amid Dis-Chem's ongoing stock slump in 2025.

The Saltzman family, one of South Africa’s richest, has taken a significant financial hit as the value of their stake in Dis-Chem Pharmacies dropped by nearly $44 million in just under three weeks. The decline follows a continued slide in the company’s share price on the Johannesburg Stock Exchange (JSE).

Family's wealth drops amid stock slump

The family holds a 29.3-percent stake in the Gauteng-based pharmacy and retail group—amounting to 252,066,319 shares. In the past 19 days alone, the market value of that stake has fallen by R839.38 million (about $43.95 million), according to data tracked by Billionaires.Africa. That brings the market value of their holding down to roughly $370 million.

This latest loss adds to an earlier blow between Feb. 7 and Mar. 10, when the value of their stake dropped from R8.65 billion ($473.47 million) to R7.82 billion ($428.09 million)—a decline of $45.37 million. The ongoing slide in Dis-Chem’s stock reflects growing unease among investors about the company’s performance and prospects in an increasingly tough economic climate.

Dis-Chem shares down 10.59%, market cap drops below $1.3 billion

Dis-Chem Pharmacies,  a household name in South Africa’s retail healthcare space, has come a long way since Lynette and Ivan Saltzman opened their first store more than 40 years ago. Today, the company runs a network of dispensaries, family clinics, wound care centers, and over-the-counter medication hubs across the country.

But the past few weeks have been tough on the pharmacy giant. Over the last 19 days, Dis-Chem’s shares have dropped by 10.59 percent on the JSE, falling from R31.43 ($1.65) on March 17 to R28.10 ($1.47) at the time of writing. That slide has knocked the company’s market value below $1.3 billion—erasing significant value for its shareholders, including the Saltzman family.

Saltzman family sees nearly $44 million wiped out

With the share price tumbling, the Saltzmans—who still own nearly 30 percent of the business—have taken a sizable hit. The value of their 29.3-percent stake has shrunk by R839.38 million ($43.95 million) in just under three weeks, down from R7.92 billion ($414.84 million) to R7.08 billion ($370.89 million).

Even so, the family remains among the wealthiest investor groups on the JSE and continues to play a major role in South Africa’s healthcare and retail pharmacy landscape.

Your money and your life

It’s been a rough year so far for Dis-Chem investors. Since the start of 2025, the stock has lost 22.16 percent of its value. That’s a sharp drop by any standard—and a reflection of wider headwinds facing the pharmacy and healthcare retail sector. A $100,000 investment in Dis-Chem at the beginning of the year would now be worth around $77,840—a loss of $22,160.

The intelligence satisfies curiosity. The paid briefings satisfy strategy.

Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.

Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.

Executive ($25/mo): Daily newsletter + Deep-Dive Reports

Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings

Subscribe now

Latest